5.1878

0.58% 0.0078

Aldeyra Therapeutics Inc (ALDX)

Overview News Price History Option Chain Financials Discussions Forecast

Aldeyra Therapeutics Inc stock is traded at $5.1878, with a volume of 215.48K. It is up +0.58% in the last 24 hours and down -2.43% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Previous Close:

$5.18

Open:

$5.12

24h Volume:

215.48K

Relative Volume:

0.41

Market Cap:

$307.80M

Revenue:

Net Income/Loss:

$-37.54M

P/E Ratio:

-5.829

EPS:

-0.89

Net Cash Flow:

$-30.33M

1W Performance:

-3.87%

1M Performance:

-2.43%

6M Performance:

+25.24%

1Y Performance:

+135.75%

1-Day Range:

$4.93

$5.23

1-Week Range:

$4.93

$5.52

52-Week Range:

$2.20

$6.5476

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name

Aldeyra Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

781-761-4904

Address

131 HARTWELL AVENUE, LEXINGTON, MA

Employee

Twitter

@aldeyraaldx

Next Earnings Date

2024-11-18

Latest SEC Filings

ALDX's Discussions on Twitter

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform
Apr-02-24	Resumed	H.C. Wainwright	Buy
Apr-27-22	Resumed	H.C. Wainwright	Buy
Feb-08-21	Initiated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Oct-30-20	Initiated	Jefferies	Buy
Oct-16-20	Initiated	BTIG Research	Buy
Sep-22-20	Initiated	Alliance Global Partners	Buy
May-12-20	Initiated	Oppenheimer	Outperform
Dec-04-18	Initiated	Citigroup	Buy
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy
Sep-26-16	Initiated	H.C. Wainwright	Buy
Jul-01-16	Initiated	Stifel	Buy
Jul-01-15	Initiated	Canaccord Genuity	Buy
Mar-25-15	Initiated	Chardan Capital Markets	Buy
Mar-20-15	Reiterated	H.C. Wainwright	Buy
Nov-18-14	Initiated	H.C. Wainwright	Buy
Jun-19-14	Initiated	Aegis Capital	Buy

View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

Oct 31, 2024

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - StockTitan

Oct 31, 2024

Oct 30, 2024

International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Oct 30, 2024

Oct 29, 2024

Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Increases By 13.3% - MarketBeat

Oct 29, 2024

Oct 28, 2024

(ALDX) Long Term Investment Analysis - Stock Traders Daily

Oct 28, 2024

Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR

Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart

Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials - openPR

Oct 21, 2024

Oct 17, 2024

(ALDX) Investment Analysis - Stock Traders Daily

Oct 17, 2024

Oct 12, 2024

Dimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Oct 12, 2024

Oct 08, 2024

Nephrotic Syndrome Drugs Market Set for Rapid Expansion with - openPR

Oct 08, 2024

Oct 07, 2024

(ALDX) Proactive Strategies - Stock Traders Daily

Oct 07, 2024

Oct 05, 2024

American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Oct 05, 2024

Oct 04, 2024

Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat

Oct 04, 2024

Oct 03, 2024

Lexington biotech resubmits dry eye drug for FDA approval a year after rejection - The Business Journals

Oct 03, 2024

Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease - MD Magazine

Oct 03, 2024

Aldeyra Therapeutics stock affirmed at Outperform on NDA submission By Investing.com - Investing.com Canada

Oct 03, 2024

Aldeyra resubmits dry eye treatment NDA to FDA By Investing.com - Investing.com Australia

Oct 03, 2024

Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment - MarketWatch

Oct 03, 2024

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - StockTitan

Oct 03, 2024

Oct 02, 2024

Aldeyra Therapeutics extends loan agreement terms - Investing.com India

Oct 02, 2024

Aldeyra Therapeutics extends loan agreement terms By Investing.com - Investing.com UK

Oct 02, 2024

Aldeyra Therapeutics, Inc. Enters into the Fourth Amendment to Loan and Security Agreement - Marketscreener.com

Oct 02, 2024

Oct 01, 2024

Aldeyra shares hold Outperform rating on pipeline progress By Investing.com - Investing.com Canada

Oct 01, 2024

What was Aldeyra Therapeutics Inc (ALDX)’s performance in the last session? - US Post News

Oct 01, 2024

Sep 30, 2024